109 180

Cited 6 times in

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer

DC FieldValueLanguage
dc.contributor.author강석민-
dc.contributor.author김지형-
dc.contributor.author김효송-
dc.contributor.author라선영-
dc.contributor.author박형순-
dc.contributor.author범승훈-
dc.contributor.author심지영-
dc.contributor.author이충근-
dc.contributor.author정민규-
dc.contributor.author정현철-
dc.contributor.author허수진-
dc.contributor.author홍그루-
dc.contributor.author박지수-
dc.date.accessioned2018-07-20T08:05:05Z-
dc.date.available2018-07-20T08:05:05Z-
dc.date.issued2017-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/160822-
dc.description.abstractTrastuzumab-induced cardiotoxicity (TIC) is the primary adverse event that limits the use of trastuzumab in HER2-positive breast cancer patients. However, the incidence and risk factors of TIC in HER2-positive gastric cancer are not known. Therefore, we evaluated the incidence and predictive factors of TIC in gastric cancer patients treated with trastuzumab in clinical practice. We reviewed cardiac dysfunction in HER2-positive gastric cancer patients between December 2005 and April 2015 in a prospectively-collected database that included prospective clinical trials at Yonsei Cancer Center, Republic of Korea. TIC was defined as an absolute decline in left ventricular ejection fraction (LVEF) of at least 10 percentage points from the baseline to a value less than 55%, as identified by a multiple-gated acquisition scan or an echocardiogram. Among the 115 patients, 70 patients (60.9%) received trastuzumab combined with chemotherapy, and 45 patients (39.1%) received chemotherapy alone as a first-line therapy. Symptomatic heart failure was not observed in either group, but a significant asymptomatic drop in LVEF was noted in five (7.1%) of the trastuzumab combined-group patients and in one (2.2%) chemotherapy-only group patient [hazard ratio (HR), 3.47; 95% confidence interval (CI), 0.40-29.8; P=0.257]. TIC was observed more frequently in elderly patients than in younger patients (HR, per age in year, 1.16; 95% CI, 1.02-1.31; P=0.019). Similar to prior observations in breast cancer, TIC in gastric cancer patients is not frequent or reversible. However, the asymptomatic drop in LVEF should be monitored continually in HER2-positive gastric cancer patients treated with trastuzumab, especially in elderly patients.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisherImpact Journals-
dc.relation.isPartOfONCOTARGET-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleCardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorJi Soo Park-
dc.contributor.googleauthorJong-Chan Youn-
dc.contributor.googleauthorChi Young Shim-
dc.contributor.googleauthorGeu-Ru Hong-
dc.contributor.googleauthorChoong-Kun Lee-
dc.contributor.googleauthorJee Hyung Kim-
dc.contributor.googleauthorHyung Soon Park-
dc.contributor.googleauthorSu Jin Heo-
dc.contributor.googleauthorSeung Hoon Beom-
dc.contributor.googleauthorHyo Song Kim-
dc.contributor.googleauthorSun Young Rha-
dc.contributor.googleauthorHyun Cheol Chung-
dc.contributor.googleauthorSeok-Min Kang-
dc.contributor.googleauthorMinkyu Jung-
dc.identifier.doi10.18632/oncotarget.18700-
dc.contributor.localIdA00037-
dc.contributor.localIdA00999-
dc.contributor.localIdA01202-
dc.contributor.localIdA01316-
dc.contributor.localIdA04576-
dc.contributor.localIdA04581-
dc.contributor.localIdA02213-
dc.contributor.localIdA03259-
dc.contributor.localIdA03606-
dc.contributor.localIdA03773-
dc.contributor.localIdA04355-
dc.contributor.localIdA04386-
dc.relation.journalcodeJ02421-
dc.identifier.eissn1949-2553-
dc.identifier.pmid28977908-
dc.subject.keywordHER2-
dc.subject.keywordcardiotoxicity-
dc.subject.keywordgastric cancer-
dc.subject.keywordincidence-
dc.subject.keywordtrastuzumab-
dc.contributor.alternativeNameKang, Seok Min-
dc.contributor.alternativeNameKim, Jee Hung-
dc.contributor.alternativeNameKim, Hyo Song-
dc.contributor.alternativeNameRha, Sun Young-
dc.contributor.alternativeNamePark, Hyung Soon-
dc.contributor.alternativeNameBeum, Seung Hoon-
dc.contributor.alternativeNameShim, Chi Young-
dc.contributor.alternativeNameLee, Choong Kun-
dc.contributor.alternativeNameJung, Min Kyu-
dc.contributor.alternativeNameChung, Hyun Cheol-
dc.contributor.alternativeNameHeo, Su Jin-
dc.contributor.alternativeNameHong, Geu Ru-
dc.contributor.affiliatedAuthorKang, Seok Min-
dc.contributor.affiliatedAuthorKim, Jee Hung-
dc.contributor.affiliatedAuthorKim, Hyo Song-
dc.contributor.affiliatedAuthorRha, Sun Young-
dc.contributor.affiliatedAuthorPark, Hyung Soon-
dc.contributor.affiliatedAuthorBeum, Seung Hoon-
dc.contributor.affiliatedAuthorShim, Chi Young-
dc.contributor.affiliatedAuthorLee, Choong Kun-
dc.contributor.affiliatedAuthorJung, Min Kyu-
dc.contributor.affiliatedAuthorChung, Hyun Cheol-
dc.contributor.affiliatedAuthorHeo, Su Jin-
dc.contributor.affiliatedAuthorHong, Geu Ru-
dc.citation.volume8-
dc.citation.number37-
dc.citation.startPage61837-
dc.citation.endPage61845-
dc.identifier.bibliographicCitationONCOTARGET , Vol.8(37) : 61837-61845, 2017-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.